The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for themanagement and evaluation of CKD recommend using an eGFRthat combines cystatin C and creatinine to stage kidney function [7].Additionally, they advise that cardiovascular risk prediction models for CKDpatients should incorporate both eGFR and proteinuria [7]. The gene discussed is CST3; the disease is chronic kidney disease.